0001209191-23-054441.txt : 20231106 0001209191-23-054441.hdr.sgml : 20231106 20231106080010 ACCESSION NUMBER: 0001209191-23-054441 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231103 FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: INGRAM DOUGLAS S CENTRAL INDEX KEY: 0001190644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 231378158 MAIL ADDRESS: STREET 1: 2525 DUPONT DR CITY: IRVINE STATE: CA ZIP: 92612 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-03 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001190644 INGRAM DOUGLAS S 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 1 1 0 0 President & CEO 0 Common Stock 2023-11-03 4 P 0 10081 78.57 A 375163 D Common Stock 2023-11-03 4 P 0 11060 79.70 A 386223 D Common Stock 2023-11-03 4 P 0 3884 80.33 A 390107 D Common Stock 2023-11-03 4 P 0 200 81.26 A 390307 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. /s/ Ryan Brown, as Attorney-in-Fact for Douglas S. Ingram 2023-11-06